close

Agreements

1 239 240 241 242 243 246
Number of results: 4911

PDF print is not allowed for data more than 3000.Please search above for fewer data.

Date Company Compound Disease Type of agreement Therapeutic area Type of Information
2011-04-04 Algeta (Norway) Genzyme (USA - MA) thorium platform tumors, cancers

R&D

Cancer - Oncology R&D agreement
2011-04-04 Selvita (Poland) The Institutes for Pharmaceutical Discovery (USA) novel chemical compounds that inhibit the activity of a novel protein target, proposed by IPD undisclosed

R&D

undisclosed R&D agreement
2011-04-04 Cellectis (France) undisclosed drug company homologous recombination technology

licensing

Cancer - Oncology Licensing agreement
2011-03-31 Cytos Biotechnology (Switzerland) United States Army (USA) malaria vaccine malaria

development

Infectious diseases - Parasitic diseases Development agreement
2011-03-30 MedImmune (USA) Inserm Transfert (France) Inserm (France)

collaboration
R&D

Cancer - Oncology - Respiratory diseases - Inflammatory diseases - Autoimmune diseases Collaboration agreement
2011-03-30 Graffinity (Germany) Shionogi (Japan) small molecule hits against an undisclosed key drug target undisclosed

R&D

undisclosed R&D agreement
2011-03-30 NovAliX (France) Graffinity Pharmaceuticals (Germany) Shionogi (Japan) novel small molecule hits against an undisclosed drug target undisclosed

R&D

undisclosed R&D agreement
2011-03-29 Protagen (Germany) Biogen Idec (USA) biomarkers multiple sclerosis

Collaboration
R&D

Autoimmune diseases - Neurodegenerative diseases R&D agreement
2011-03-28 MolMed (Italy) Fondazione Telethon (Italy) gene therapy treatments for six rare genetic diseases metachromatic leukodystrophy (MLD) - Wiskott-Aldrich syndrome (WAS) - beta-thalassemia mucopolysaccharidosis type I (MPS I) - globoid leukodystrophy (GLD) - chronic granulomatous disorder (CGD)

development
manufacturing
production

Rare diseases - Genetic diseases Development agreement
2011-03-25 AstraZeneca (UK) Senectus Therapeutics (UK) screening of a selection of AstraZeneca’s chemical compound library

services
collaboration

Cancer - Oncology Services contract
2011-03-23 Sanofi-Aventis (France) The Vision Institute (France)

R&D

Ophtalmological diseases R&D agreement
2011-03-23 Debiopharm (Switzerland) Aurigene (India) Debio 1142

licensing
development
commercialisation

Cancer - Oncology Licensing agreement
2011-03-22 Vivalis (France) Okairos (Italy) EB66® cell line

licensing

Infectious diseases Licensing agreement
2011-03-21 Karo Bio (Sweden) Zydus Cadila (India) novel anti-inflammatory drug compounds which affect glucocorticoid receptors in a selective manner.

R&D

Inflammatory diseases R&D agreement
2011-03-21 Dako (Denmark) Epitomics (USA) rabbit monoclonal antibodies to be used in diagnosing cancer and in developing predictive assays for cancer patients (companion diagnostics)

collaboration

CancerOncology Collaboration agreement
2011-03-17 Epistem (UK) Sanofi-Aventis (France) biomarker gene expression profiling and immunohistochemistry technologies

R&D

licensing

Licensing agreement
2011-03-17 Lonza (Switzerland) Athera Biotechnologies (Sweden) PC-mAb (monoclonal antibody to phosphorylcholine) acute coronary syndrom

development
manufacturing
production

Cardiovascular diseases Development agreement
2011-03-16 MorphoSys (Germany) Boehringer Ingelheim (Germany) MOR208 ( anti-CD19 monoclonal antibody) chronic lymphocytic leukemia and potentially other B-cell malignancies

manufacturing
production

Cancer - Oncology Production agreement
2011-03-15 Depomed (USA) Boehringer Ingelheim (Germany) Acuform® Technology and Glumetza® Data type 2 diabetes

licensing

Metabolic diseases Licensing agreement
2011-03-15 InhibOx (UK) Cosmic Discoveries (India) drug discovery services

collaboration

Collaboration agreement